Medicus Pharma Ltd. Common Stock
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Medicus Pharma Ltd. (NASDAQ:MDCX) is a biotech and life sciences company that focuses on accelerating the clinical development and commercialization of novel and disruptive therapeutic assets through acquisitions, partnerships and targeted investments. The company develops SkinJect, a patented dissolvable doxorubicin-containing microneedle array (D-MNA) as a non-invasive treatment for basal cell carcinoma and other non-melanoma skin cancers via ongoing Phase 2 trials including SKNJCT-003 in the United States and Europe and SKNJCT-004 in the United Arab Emirates; through its August 2025 acquisition of Antev Limited, it now advances Teverelix trifluoroacetate, a next-generation long-acting GnRH antagonist formulated as a microcrystalline suspension for sustained release every six weeks to treat acute urinary retention relapse in enlarged prostate patients and advanced prostate cancer in high cardiovascular-risk individuals, with FDA-approved Phase 2b study designs for 390 and 40 patients respectively. Medicus Pharma operates across three continents with clinical activities in the United States, United Kingdom, United Arab Emirates and Europe; founded in 2008, it maintains headquarters in Conshohocken, Pennsylvania, with prior Canadian operations in Toronto. Recent developments include the September 2025 acquisition of 98.6% of Antev for $2.97 million in cash plus 1.6 million shares and up to $65 million in contingent milestone payments tied to FDA approvals, adding Teverelix and industry veteran Patrick J. Mahaffy to its board; a strategic October 2025 collaboration with the Gorlin Syndrome Alliance to pursue FDA Expanded Access for SkinJect in patients with multiple recurrent basal cell carcinomas; an August 2025 non-binding memorandum of understanding with Helix Nanotechnologies to explore co-development of thermostable mRNA infectious disease vaccines combining microneedle delivery; positive FDA Type C meeting feedback in September 2025 supporting the 505(b)(2) pathway for SkinJect; full UK regulatory approvals in November 2025 to expand SKNJCT-003; and first patient dosing in SKNJCT-004. Subsidiaries include SkinJect Inc. and Antev Limited, with operations targeting unmet needs in oncology and urology for improved patient safety, efficacy and compliance.
Medicus Pharma advances SkinJect program with FDA submission targeting Gorlin Syndrome
Medicus Pharma Advances SkinJect® into Registrational Development for Gorlin Syndrome
Medicus Pharma advances SkinJect program with FDA submission targeting Gorlin Syndrome
US stocks set for further gains despite inflation concerns, says UBS
Nasdaq hits record high as S&P 500 also climbs on US-Iran deal hopes
Medicus Pharma secures up to $22M in non-dilutive financing facility
Medicus Pharma Announces $22 Million Non-Dilutive Financing
Synopsys delivers beat-and-raise, shares fall weakness in chip IP business
Medicus Pharma sees catalyst-rich year ahead as SkinJect and Teverelix progress
Medicus Pharma sees catalyst-rich year ahead as SkinJect and Teverelix progress
Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
JD Sports up 3% after hikes returns after 'resilient' performance in tough year - UPDATE
Medicus Pharma highlights positive dose-response in updated skin cancer trial results
Uber shares surge after strong first-quarter results, bullish guidance
Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response
Medicus Pharma highlights positive dose-response in updated skin cancer trial results
Medicus Pharma lobbies Congress on SkinJect regulatory pathway for rare Gorlin syndrome
Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill
Medicus Pharma lobbies Congress on SkinJect regulatory pathway for rare Gorlin syndrome
Medicus Pharma advances Skinject in rare disease – ICYMI